Stonegate Capital Partners has updated its coverage on Burcon Nutrascience Corporation (TSX: BU), highlighting the company's transition from commissioning to early utilization at its Galesburg facility. Burcon has completed commissioning and launched commercial production across its Peazazz pea protein, Puratein C canola protein, and FavaPro fava protein lines during fiscal year 2026. This milestone marks a critical shift as the company focuses on volume growth and fixed-cost absorption.
Revenue for the fourth quarter of fiscal 2026 reached $0.83 million, up from $0.74 million in the third quarter. Management indicated that current-quarter sales are tracking toward approximately 50% sequential growth based on April and May activity. Burcon also set a new production record, with daily output roughly 60% above January to March levels. As volume builds, the margin opportunity is expected to come from better utilization, steadier production cadence, and the removal of start-up costs from the run-rate cost structure, rather than pricing alone.
Customer traction is broadening, with over 30 purchasing customers and more than 200 active projects across pea, canola, and fava applications. The company's funding supports the Galesburg scale-up, with $6.9 million completed, $3.0 million undrawn, and management targeting $10 million in calendar year 2026 sales. For more details, see the full announcement here.
Burcon's progress reflects a pivotal phase as it moves from commissioning to utilization ramp mode. The sequential revenue growth and production records demonstrate operational improvements, while the expanding customer base and active projects suggest strong market demand. The company's ability to achieve higher sales volumes and better fixed-cost absorption will be key to margin expansion. With a clear focus on scaling production and leveraging its diversified protein portfolio, Burcon is positioning itself for sustained growth in the plant-based protein market.
